Next Century Growth Investors’s Neurocrine Biosciences NBIX Stock Holding History

Next Century Growth Investors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-72	Closed	-$3K	–	166
2016 Q3	$3K	Sell	72 -303	-81%	-$15.1K	﹤0.01%	176
2016 Q2	$17K	Hold	375	–	–	﹤0.01%	171
2016 Q1	$14K	Sell	375 -222	-37%	-$8.81K	﹤0.01%	164
2015 Q4	$33K	Sell	597 -46,224	-99%	-$2.35M	﹤0.01%	174
2015 Q3	$1.86M	Buy	+46,821	New	+$2.26M	0.08%	162

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Next Century Growth Investors's NBIX Position: Q4 2016 in Review

Next Century Growth Investors sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 72 shares — an estimated $3K sold.

Next Century Growth Investors first reported a position in NBIX in Q3 2015 and held it in 5 quarters. The position peaked at $1.86M in Q3 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

Next Century Growth Investors reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
Next Century Growth Investors sold 72 Neurocrine Biosciences shares in Q4 2016, an estimated $3K.
Next Century Growth Investors first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 5 quarters.
Next Century Growth Investors's Neurocrine Biosciences position peaked at $1.86M in Q3 2015.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Next Century Growth Investors's 13F filing for Q4 2016, filed 14 Feb 2017.